

Our Reference: **C19RM 2021 FUNDING_ COSTA RICA**

Geneva, 16 July 2021

Mrs. Ruth Linares Hidalgo
Avenida 10, calle 37
Apartamentos Orosi, Los Yoses Sur
San José
Costa Rica

Subject: 2021 COVID-19 Response Mechanism Additional Funding for Costa Rica

Dear Mrs. Linares Hidalgo

Thank you for your commitment in the fight against the COVID-19 pandemic.

The Global Fund has reviewed your COVID-19 Response Mechanism (**C19RM**) Full Funding Request and approved US\$ 2,200,662 of additional investments for your country's COVID-19 response (**C19RM Additional Award**). The Global Fund has also approved the use of US\$ 7,014¹ from the remaining C19RM funding awarded to your country in 2020, for the period after 30 June 2021 (**Remaining C19RM 2020 Award**). This brings your total C19RM award (all C19RM 2020 awards received to date) to US\$ 2,392,729 (**C19RM Total Award**).

After careful review, we regret to inform you that the Global Fund is unable to approve US\$ 90,262 of the funding included in your Full Funding Request on the basis that this amount of grant management costs, including human resources, was not clearly justified in the funding request.

Please note that the C19RM Additional Award is additional to your country's 2020-2022 allocation and any C19RM funding awarded to your country to date. The C19RM Additional Award and Remaining C19RM 2020 Award will become part of the grant (**Grant**) listed in the table below:

Grant	Amount Awarded (US\$)	Implementation Period dates
CRI-H-HIVOS	2,200,662	01/07/2021 to 30/06/2024

The C19RM Additional Award and Remaining C19RM 2020 Award will cover the approved interventions and activities set out in the Funding Request C19RM Budget (**C19RM Budget**) and the C19RM Health Products Management Template (**C19RM HPMT**) enclosed with this letter. Additional recommendations relating to the C19RM Additional Award are set out in Annex 1 to this letter.

While the deadline for use of the C19RM Additional Award and Remaining C19RM 2020 Award is **31 December 2023**, recipients are expected to use these funds **as soon as possible** to address urgent needs and only for the purposes for which the funding was approved and pursuant to the

¹ This is a provisionally approved amount as at the date of this letter. The actual amount of C19RM funds remaining from 2020 is subject to confirmation after verification by the Global Fund.

terms and conditions of the corresponding grant agreements for the Grant (**Grant Agreement**) and this letter.

The C19RM Additional Award must be incorporated into the Grant, by no later than 16 September 2021. If the Implementation Letter is not signed by this date, the payment of any purchase requisitions raised under the Global Fund's Pooled Procurement Mechanism for approved health products will be deducted from the C19RM Additional Award and/or the products may be rerouted.

In the meantime, given the urgency of the nature of the activities for which the C19RM funds were awarded, the Principal Recipient may utilize any available uncommitted funds under the Grant to initiate implementation of the approved C19RM activities in accordance with the terms and conditions of the Grant Agreement and this letter. Unless otherwise agreed by the Global Fund in writing, by initiating implementation of the approved C19RM activities, the relevant Principal Recipient is deemed to have accepted the terms and conditions of the relevant Grant Agreement and the conditions applicable to each such Principal Recipient in this letter.

The Global Fund Country Team will be in touch with each Principal Recipient to discuss the process for initiating implementation of the approved C19RM activities.

We stand ready to support Costa Rica in responding to the COVID-19 pandemic, which threatens to destroy years of progress against HIV, TB and malaria. To defeat COVID-19, protect progress against HIV, TB and malaria, and save lives, we must unite to fight.

Yours sincerely



Mark Eldon-Edington

Division Head

Grant Management

Cc: Humanist Institute for Co-operation with Developing Countries

encl: Annex 1 – Recommendations to use of the C19RM Additional Award and the
Remaining C19RM 2020
C19RM HPMT
C19RM Budget
C19RM Procurement Progress Reporting Template

Annex 1
Recommendations to use of the C19RM Additional Award and the Remaining C19RM 2020 Award

Legal Requirements to form part of Grant Agreement

1. C19RM Health Products Reporting

- a. The Principal Recipient shall adhere to the procurement channel arrangements approved in the enclosed C19RM HPMT for each relevant Grant Agreement and shall not make any amendments to these arrangements without the prior written approval of the Global Fund.
- b. The Principal Recipient shall, by the relevant procurement reporting date (“C19RM Procurement Progress Reporting Date”), complete and submit to the Global Fund’s satisfaction, the C19RM Procurement Progress Reporting Template (enclosed with this letter) setting out the: (i) purchase order issue date; (ii) vendor-promised delivery date; (iii) date of product dispatch from the manufacturer; and (iv) date of product delivery for each:
 - i. C19RM Strategic Health Product and Mainstream Health Product procured outside of the Global Fund’s Pooled Procurement Mechanism (“PPM”); and
 - ii. C19RM Local Sourcing Advised Products with Enhanced Reporting,

as such terms are defined in the Global Fund C19RM Guidelines (as may be amended from time-to-time and notified to the Principal Recipient in writing).¹

The C19RM Procurement Progress Reporting Date for these products procured through national sourcing channels is no later than 10 January after the end of each calendar year of the Implementation Period.

The C19RM Procurement Progress Reporting Date for these products procured through non-PPM pooled procurement channels is no later than the following quarterly dates of each calendar year of the Implementation Period: 10 January, 10 April, 10 July and 10 October respectively, with the final C19RM Procurement Progress Reporting Date being the relevant quarterly date that falls immediately after the Implementation Period end-date.

- c. The Principal Recipient shall take all appropriate and necessary actions to ensure that any relevant Sub-recipient, supplier, contractor or agent provides the Principal Recipient with such information as may be required for the Principal Recipient to comply with its obligations set out in paragraph 1 (b) above.
2. The Principal Recipient acknowledges and agrees that the Global Fund may request the LFA to undertake a review of health products and related support services (including technical support and warranty and maintenance services) procured through national sourcing channels under the C19RM Additional Award to ensure that the health products and services procured are value for money and also that the procurements will be conducted in accordance with Article 5 of the Global Fund Grant Regulations (2014).
 3. The Principal Recipient acknowledges that the LFA will undertake periodic reviews to monitor warehousing, distribution and usage of health products procured under the C19RM Additional Award (including pre-delivery reviews to confirm supply chain arrangements). The scope of the reviews may be extended to specific supply chains such as cold chain, and laboratory supply chain.

Other recommendations to be addressed during implementation

1. By 31 March 2022, the Principal Recipient, in consultation with the Ministry of Health and CCM shall submit a sustainability plan detailing which activities will transition to government funding after the end of the Grant.
2. Prior to the procurement of local health product procurements, the Principal Recipient is requested to develop detailed product specifications which are complete, comprehensive and accurate, and to ensure that suppliers provide detailed product information, as well as proof that products are aligned with WHO guidelines and quality standards.
3. The Principal Recipient is expected to work with the Ministry of Health of Costa Rica and the CCM to ensure periodic reporting on the country's COVID-19 burden in accordance with World Health Organization guidance. These data are to be reported via Excel using the form "[Global Surveillance of COVID-19: WHO process for reporting aggregated data- V2](#)" or through the dedicated submission weekly surveillance platform (for further information please email covidsurveillance@who.int). The dataset should include age and gender of cases and deaths, and infections and deaths among health workers. Compliance with such reporting will be monitored by the Global Fund using the WHO COVID-19 surveillance dashboard on an ongoing basis to facilitate grant management and investment decisions.